EVALUATION OF ANALGESIC ACTIVITY OF ROOTS OF PICRORHIZA KURROA

Methodology:-The selected drug from the authentic literature is in form of dried roots of Picrohiza kurroa belonging to family scrophulariaceae.  Analgesic  activity of root powder is extracted with alcohol for 7 days.  The extracts in these dose levels of 250 mg/kg, 500 mg/kg were tested.  The analgesic activity was studied by using the Hot plate and Acetic acid induced-writhing method in albino mice of either sex. The writhing are measured within 10 min. Results:- The 500mg/kg drug of picrorhiza kurroa having similar effect to the standard drug pentazocin at ½ hrs.pentazocin is agonist-antagonist type of analgesic drug.in hot plate method the 500mg/ kg drug of picrorhiza kurroa is effective at the ½ hrs than the 250mg/ kg Conclusions:-Dose effective of ethanolic extract of  picrorhiza kurroa 500 mg/kg. by Hot    plate method and Acetic acid induced writhing method

Modelling solute transport in soil columns using advective-dispersive equations with fractional spatial derivatives

Solute transport in soils is commonly simulated with the advective–dispersive equation, or ADE. It has been reported that this model cannot take into account several important features of solute movement through soil. Recently, a new model has been suggested that results in a solute transport equation with fractional spatial derivatives, or FADE. We have assembled a database on published solute transport experiments in soil columns to test the new model. The FADE appears to be a useful generalization of the ADE. The order of the fractional differentiation reflects differences in physical conditions of the solute transport in soi

Pichia pastoris versus Saccharomyces cerevisiae:a case study on the recombinant production of human granulocyte-macrophage colony-stimulating factor

BACKGROUND: Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) is a glycoprotein that has been approved by the FDA for the treatment of neutropenia and leukemia in combination with chemotherapies. Recombinant hGM-CSF is produced industrially using the baker's yeast, Saccharomyces cerevisiae, by large-scale fermentation. The methylotrophic yeast, Pichia pastoris, has emerged as an alternative host cell system due to its shorter and less immunogenic glycosylation pattern together with higher cell density growth and higher secreted protein yield than S. cerevisiae. In this study, we compared the pipeline from gene to recombinant protein in these two yeasts. RESULTS: Codon optimization in silico for both yeast species showed no difference in frequent codon usage. However, rhGM-CSF expressed from S. cerevisiae BY4742 showed a significant discrepancy in molecular weight from those of P. pastoris X33. Analysis showed purified rhGM-CSF species with molecular weights ranging from 30 to more than 60 kDa. Fed-batch fermentation over 72 h showed that rhGM-CSF was more highly secreted from P. pastoris than S. cerevisiae (285 and 64 mg total secreted protein/L, respectively). Ion exchange chromatography gave higher purity and recovery than hydrophobic interaction chromatography. Purified rhGM-CSF from P. pastoris was 327 times more potent than rhGM-CSF from S. cerevisiae in terms of proliferative stimulating capacity on the hGM-CSF-dependent cell line, TF-1. CONCLUSION: Our data support a view that the methylotrophic yeast P. pastoris is an effective recombinant host for heterologous rhGM-CSF production

A Study on mHealth Innovations through the Lens of Patent Analysis

312-322Mobile health also referred to as mHealth is a broader term that includes mobile computing, medical sensor, communication technologies, and other wireless technologies associated with healthcare. Mobile health apps are becoming more popular due to their varied applications and have the potential to greatly improve the healthcare segment in any country. In this context, the present study attempts to provide a comprehensive picture of innovation trends in mHealth domain through patent landscape analysis. Further, it attempts to identify the major challenges with respect to patenting and protecting innovation in India. The analysis shows that there is an upward trend in patenting since 2002 onwards, and in addition to big private entities, start-ups and academic institutions are also having a major contribution to innovations in mHealth sector. However, there are inherent challenges in patenting an ICT technology which was also evident in our study with respect to selected mHealth app patents. A concerted effort in enhancing IPR capture as well as appropriate support mechanism is the need of the hour to promote and effectively implement mHealth in the countr

Not Available

Not Availablelaakh vanon evan up -van kshetron mein praakrtik roop se utpann hone vaale saath hee kisaanon ke kheton mein paaye jaane vaale paripaalak vrkshon par utpaadit kiye jaate hain.Not Availabl